Sleep, Adenosine and Caffeine as Tools for The Early Diagnosis of Parkinson Disease

Rafael J. Salin-Pascual*

Department of Psychiatry and Mental Health. School of Medicine. National Autonomous University of Mexico

Abstract: The information that has developed regarding Parkinson's Disease (PD) allowed to understand that there is a period of this disease, perhaps at least a decade, in which the classical features of PD are not detected as such, however, there are evidence of a series of non-motor manifestations, among which are: anosmia, constipation, psychiatric disorders such as major depression, generalized anxiety, and rapid eye movement sleep behavior disorder (RBD).

On the other hand the understanding of physiological mechanisms of sleep-wake cycle, have become remarkable tools to explore neurological and psychiatric disorders and complemented the information and treatments for those disorders.

There is evidence that RBD can occur in half of people who will develop PD, about 10 year letter. The role of adenosine in sleep and caffeine intolerance is other aspects that are evident in the relation between PD and sleep. The detection of PD in early stages, may allow the implementation of the type of therapeutic strategies for neuroprotection. The general goal would be delay or reduce the clinical manifestations of PD in some patients.

Keywords: Parkinson Disease, RBD, Adenosine, Caffeine, Sleep.

INTRODUCTION

Sleep could be seen as a complex behavior that in humans could give us some information about physiological process as circadian rhythms, neuroendocrine system, body energy regulation and at the same time, by studying sleep in pathological process, give us some light into the physiopathology of such diseases. In the last half-century sleep research both basic and clinical, has increased our knowledge about mechanism and functions of such behavior. Because humans spend about one-third of each day in sleep, that could be a powerful tool for to understand morbid process [1-3]

The central goal of this review is to present some findings about the relationship between Parkinson's disease, sleep mechanism, and adenosine as sleep factor, its receptors, the prevalence of some sleep disorders in that neurodegenerative affection, and to figure out if the hypersensitivity to caffeine, could be a cue for to organize some forms of PD with premorbid sleep disorders as well as anxiety problems. Those connections could be useful in to employ some strategies for identifying premorbid cases, that will help us to implement approaches as neuroprotection that could slow down the natural course of that disease.

PARKINSON DISEASE

Parkinson Disease (PD) is an incurable progressive neurological condition caused by a degeneration of dopamine-producing cells at the substantia nigra (SN). The most common symptoms of that condition include slowness of movement, tremor and muscle stiffness; other symptoms include sleep difficulties, depression and anxiety. Parkinson's is usually controlled by medication but other treatments and therapies, such as occupational therapy, physiotherapy and speech and language therapy, can also be effective in controlling and managing symptoms. [4]. Recently Deep Brain Stimulation (DBS) have been developed as an important therapeutic strategy for help some PD patients. Those with intractable motor fluctuations, intractable tremor, or intolerance of medication, and adverse effects are good candidates for DBS [5-7].

Initial estimates based on nigra neuropathological findings or striatal dopamine imaging suggested a five to six year of preclinical period. Lewy body pathology in other neuronal populations preceding nigra involvement suggests that the preclinical phase may be much longer [8]. Epidemiologic studies of non-motor manifestations, such as constipation, anxiety disorders, and rapid eye movement sleep behavior disorder (RBD), and anemia; suggest that the preclinical period extends at least 20 years before the motor manifestations [9-11]. Olfactory impairment and depression are also two problems that anticipate motor manifestations [12].

The pathological process in the nervous system that will lead to PD begins decades before the typical motor symptoms and by the time the diagnosis is made, about 70% to 80% of striatal dopamine (DA) and at least one-third of SN neurons and striatal dopaminergic fibers are already lost [13].

PD is a multisystem disorder though its more relevant symptoms derive from a disruption of the physiology of cortical-basal ganglia-thalamic-cortical circuits [14, 15].
These circuits function as a highly ordered and interconnected network with multiple feedback regulatory mechanisms. There are several sub circuits with intrinsic neurophysiological properties and regulatory systems [15]. Compensation can be illustrated by the well-known fact that the majority of acute and focal lesions of basal ganglia are unnoticed by the patient until the affected structures are beyond compensation. Moreover, when they are symptomatic (i.e., hemiballismus by a sub-thalamic lesion), a relatively rapid recovery occurs. Thus, these structures are extremely plastic. Plasticity refers to the ability of the nervous system to adapt to new situations by changing the effectiveness of transmission in neural circuits [16, 17]. It is almost always regarded as a useful phenomenon that is important in learning and memory and could potentially compensate for dysfunction after injury.

Several characteristics of PD are clear expressions of compensatory mechanisms. Firstly, pathological studies have showed that a proportion as high as 30% of normal individuals has alpha-synuclein inclusions in their brains and that 15% have Lewy bodies. Secondly, PD has a long pre-symptomatic period of at least 5–6 years. This suggests that many neurons in the SNpc can die before they are missed at the clinical level. Parkinsonian signs appear when dopaminergic neuronal death exceeds a critical threshold (70–80% of striatal nerve terminals and 50–60% of SN cell bodies). Thirdly, its progression is slow and gradual. Finally, there is a non-linear relationship between dopamine-containing neuron loss and functional impairment [18]. These points result largely from adaptive neurochemical changes that occur within the striatum or in other parts of the basal ganglia circuits [18].

Some of the premorbid symptoms of PD (also known as non-motor symptoms) are the following:

**Anosmia:** Olfactory dysfunction is an appealing biomarker for PD because of the high prevalence (>90%) among PD patients and the relative ease of testing, as compared to other putative biomarkers such as neuroimaging of the dopamine system. Hyposmia develops during the early stages of PD and, therefore, may be one of the most sensitive markers for the early diagnosis of PD [19].

**Constipation:** Symptoms of dysautonomia develop in most patients during the course of PD, and constipation is probably the most common manifestation. Constipation relates to impaired colonic mobility and is not simply attributable to medications. Previous authors have commented that constipation may sometimes precede the initial motor manifestations of PD. This finding was borne out in the Honolulu-Asia Aging Study, in which men without PD or dementia were prospectively followed up after completing a bowel-movement questionnaire. Incidental Lewy body pathology was present in nearly one-fourth of individuals with constipation (one bowel movement daily) compared with 6.5% of individuals without it [20].

Anxiety and other psychiatric disorders: Several case-control or cohort studies suggested that anxiety may be one of the earliest manifestations of PD. First, in a population-based, case-control studies, anxiety diagnoses documented in historical medical records were significantly associated with later PD, [21].

Several investigators have also commented on premorbid parkinsonian personality. Twin and other studies have suggested that patients with PD, even since childhood, are more introverted, serious, cautious, tense, nervous, obsessive-compulsive, inflexible, industrious, and honest; that they avoid risk-seeking behavior such as smoking; and that they are less likely to exhibit impulsive or novelty-seeking behavior compared with controls. Despite these characteristics psychological and personality changes occurring even in early stages of PD, they are relatively nonspecific, and it is unlikely that these traits can be used to reliably predict increased risk of PD in the general population [22]. Sleep problems are part of the non-motor symptoms.

**SLEEP DISORDERS AND PD**

PD patients often experience sleep symptoms like insomnia, parasomnias, and daytime somnolence early on and when motor manifestations are observed. Daytime sleepiness, restless leg syndrome, periodic limb movements disorder and REM sleep behavior disorders are the more prevalent. The last one was figured out as one of the early manifestations of PD even before any motor symptoms. RBD is characterized by vigorous movements during REM sleep, and may also be caused by neuronal degeneration in the central nervous system (CNS) [23]. There are also some cases of late-onset sleep walking [24].

There are some proposal that about at least 50% of patients with RBD could develop PD, and it was hypothesized that many of these potential early PD markers (anosmia, autonomic symptoms, psychiatry and soft neurological signs plus cognitive decline), would be also early present in patients with idiopathic RBD [25, 26]. In 2006, it was reported, as the results of a small case control study that documented substantial abnormalities of olfaction, color vision, autonomic function and motor function in patients with idiopathic RBD [27].

There were evaluated an array of potential PD predictive markers in 159 subjects; including 68 with idiopathic RBD, 36 controls, 34 PD patients with RBD and 21 PD patients without RBD. Compared with controls, patients with idiopathic RBD demonstrated substantial olfactory loss. Olfaction was more impaired in PD than idiopathic RBD and did not differ between PD patients with, or without, RBD. Numerous measures of motor function including the Unified Parkinson Disease Rating Scale, alternate tap, Purdue Peg Board and Timed “Up and Go”, were impaired in idiopathic RBD compared with controls. All of these motor measures were worse in PD than with idiopathic RBD, regardless of RBD status. Autonomic symptoms and systolic blood pressure drop was impaired in patients with idiopathic RBD compared with controls. Orthostatic abnormalities in PD were found in the group with RBD. However, Parkinson's patients without RBD were not different than controls and had less impairment than those with idiopathic RBD and PD patients with RBD. This study could give an idea that RBD is a premorbid condition that could evolve to PD. There are some recent research and reviews that support that [28-30].

There are some different approaches in order to clarify the relationship between sleep and PD. Does sleep duration could be related to PD? What are the relationship between
long sleepers and short sleepers and the incidence of PD? Two groups of nurses were studied. The study follows a working rotating night shift, and it was looking for the association with the risk of PD among 84,794 female nurses who reported years of night shift work in 1988 (the US Nurses' Health Study). After 975,912 person-years of follow-up (1988–2000), 181 incident PD cases were documented. Compared with nurses who never worked rotating night shifts, those with 15 years or more of night shift work had a 50% lower risk of PD after adjustment for age and smoking. Sleep duration was positively associated with PD risk: The relative risk was 1.84 (95% confidence interval: 0.99, 3.42) when comparing nurses who reported 9 or more hours of sleep per day with those who slept 6 hours or less (p trend = 0.005). These data suggest that working night shifts may be protective against PD or that low tolerance for night shift work is an early marker of PD [31].

Another approach for to understand the relationship between sleep and PD is looking into the phenomenology of RBD. Are PD patients showing some motor problems when they are acting their dreams content?

In the following study [32], it was interviewed one hundred consecutive non-demented patients with PD and their bed partners using a structured questionnaire assessing the presence of RBD. They rated the quality of movements, voice, and facial expression during REM sleep as being better, equal or worse than in awake as in the “ON levodopa condition”. Nighttime sleep and movements were videotaped during polysonography in 51 patients to evaluate the presence of bradykinesia, tremor, and hypophonia during RBD. Fifty-nine patients had clinical RBD with 53/59 bed partners that were able to evaluate them. All 53 (100%) reported an improvement of at least one component of motor control during RBD. By history, movements were improved in 87% patients (faster, 87%; stronger, 87%; smoother, 51%), speech was better in 77% patients (more intelligible, 77%; louder, 38%; better articulated, 57%) and facial expression was normalized in 47% patients. Thirty-eight per cent of bed partners reported that movements were ‘much better’, even in the most disabled patients. Video observations purposeful of motor activity at the moment of REM sleep demonstrate that no rigidity was observed, also surprisingly fast, ample, coordinated and symmetrical motor activity, without obvious sign of Parkinsonism. The movements were, however, jerks, violent and often repetitive. While all patients had asymmetrical parkinsonism when awake, most of the time they used the more disabled arm, hand and leg during the RBD (P = 0.04). Movements involved six times as often the upper limbs and the face as the lower limbs (OR: 5.9, P = 0.004). The percentage of time containing tremor EMG activity decreased with sleep stages from 34.9 to 15.5% during wakefulness, to 3.6 to 5.7% during non-REM sleep stages 1–2, 1.4 to 3.0% during non-REM sleep stages 3–4, and 0.06 to 0.2% during REM sleep (in this last case, it was subclinical tremor) [32].

The restored motor control during REM sleep suggests a transient ‘levodopa-like’ reestablishment of the basal ganglia loop. Alternatively, Parkinsonism may disappear by REM sleep-related disjunction between pyramidal and extrapyramidal systems. The researcher in this study suggests the following model: the movements during the RBD would be generated by the motor cortex and would follow the pyramidal tract bypassing the extrapyramidal system.

These movements would eventually be transmitted to lower motor neurons because of brain stem lesions interrupting the ponto-medullary pathways which mediate the REM sleep atonia [32].

Hypersomnia or daytime sleepiness is also a premorbid manifestation in PD. There are also some narcoleptic-like symptoms. PD is preceded and accompanied by daytime sleep attacks, nocturnal insomnia, REM sleep behavior disorder, hallucinations and depression, symptoms that are frequently as troublesome as the motor symptoms. Some of these symptoms are present also in narcolepsy, which is linked to a selective loss of hypocretin (Hcrt) neurons. With a sample of brain slides from PD patients and normal controls, it was found an increasing loss of hypocretin cells with disease progression [33, 34]. Similarly, there was an increased loss of melanin concentrating hormone (MCH) cells with disease severity. There are also some other neurotransmitters and proteins loss in PD: Hert; MCH; alpha synuclein and glial fibrillary acidic protein cells were lost throughout the anterior to posterior extent of their hypothalamic distributions [34].

Adenosine and adenosine deaminize were observed with differences in PD and normal controls. Adenosine deaminize (ADA) and its iso-enzyme activities in serum were measured together with peripheral lymphocyte subsets in 42 patients with idiopathic Parkinson’s disease. The total and ADA 2 activities were significantly higher than normal controls. As regards the peripheral lymphocyte subsets, the proportion of OKT 10 + cells (activated T lymphocytes) and the proportions of interleukin-2 receptor + and HLA-DR + cells (mainly activated T lymphocytes) were significantly higher than normal controls. On the other hand, OKT 10 + cells demonstrated a significant correlation not only with total ADA but also with ADA 2 activity [35].

ADA has variation in the brain and that maybe related to the individual pattern of the sleep-wake cycle (i.e., long and short sleepers). It has been demonstrated that adenosine agonists and antagonists strongly impact upon sleep [36, 37]. In addition, the level of adenosine varies across the sleep/wake cycle and increases following sleep deprivation. ADA is a key enzyme involved in the metabolism of adenosine. It was questioned, therefore, whether there are differences in ADA activity in brain regions relevant to sleep regulation.

The regional differences in ADA activity correlate with variations in the level of its mRNA [38, 39]. This suggests that spatial differences in ADA activity are the result of changes in the expression of the ADA gene. We postulate that ADA plays an important role in the mechanism that controls regional concentration of adenosine in the brain and thus, it is a part of the sleep-wake regulatory mechanism that could be individual related.

**ADENOSINE AND CAFFEINE IN PARKINSON DISEASE**

Sleep begins by the sleep-active cells in the hypothalamus. Adenosine and some pharmacological agents
that induced sleep-like stages could be working in the same neuroanatomical regions that have been proposed as part of sleep induced mechanisms. The microinjection of triazolam into such sites [40, 41] induced sleep. Injections of triazolam, in the medial preoptic area (MnPO) at the anterior hypothalamus, consistently enhanced sleep. This is an anatomically specific effect, while the injections into nearby structures (the lateral preoptic area, the horizontal limb of the diagonal band of Broca) had no effect on sleep. The basal forebrain and anterior hypothalamus have long been thought to have an important role in sleep regulation [42].

Neurons in that area also have a response to adenosine as well as benzodiazepines, and they are numerous in the preoptic anterior hypothalamic (POAH) (located medial to the cholinergic zone of the BF) where they comprise about 25% of the cells recorded in vivo. Lesions of the POAH in rats and cats produce significant reductions in sleep. Microinjections of somnogens such as adenosine and prostaglandin D2 into the POAH significantly increase sleep [43].

Segregated groups of sleep-active neurons are localized in the ventrolateral preoptic area (VLPO) and median preoptic area (MnPO) [44]. These cells express Gama-amino-butyric acid (GABA), and in the VLPO neurons, GABA is co-localized with galanin. Data from c-fos studies as well as from electrophysiological and in vivo microdialysis studies suggest that VLPO neurons are active only during spontaneous sleep and recovery sleep, but not during periods of wakefulness preceding sleep, e.g., during SD, suggesting that these neurons may not be involved in the mediation of the sleepiness associated with prolonged wakefulness, but rather in some aspect of maintenance or execution of sleep. However, the number of GABAergic neurons expressing c-Fos in the MnPO increase after 2 h SD as compared with spontaneous sleep and recovery sleep [45].

Adenosine is the end product of hydrolysis of the universal “energy currency”, ATP, thus energy consumption and adenosine formation are directly related. It is safe to postulate that energy metabolism is somehow involved in the regulation of sleep, since all normal brain functions require undisturbed energy metabolism. Several indirect lines of evidence suggest that energy metabolism decreases during sleep. Whether energy metabolism has a direct role in sleep regulation remains questionable, although many experiments support this notion. The so-called “homeostatic theory”, stated that the depletion of brain glycogen stores during prolonged wakefulness leads to increase in sleep need [46]. However, recently this hypothesis has been modified. Lactate produced by astrocytes is the main source of energy to neurons, which introduces another variable that was not figured out before.

A more recent hypothesis suggests that neurons can use lactate as an energy source and even favors lactate over glucose. During times of activation the utilization of lactate as a source of energy for neuronal activation has been supported by a number of experiments. The core of this hypothesis is that upon neuronal activation, astrocytes metabolize glucose to lactate, which is then transported to neurons via selective transporters and that neurons use it as energy substrate instead of glucose. As the lactate that neurons utilize is produced by astrocytes and is transferred to neurons via the extracellular space, In Vito micro dialysis measurement of lactate can be used as a marker of neuronal activation [47].

The extracellular concentration of adenosine increases in the cortex and basal forebrain during prolonged wakefulness and decreases during the sleep recovery period. Therefore, adenosine is proposed to act as a homeostatic regulator of sleep and to be a link between the humoral and neural mechanisms of sleep-wake regulation. Both the adenosine A1 receptor (A1R) and A2AR are involved in sleep induction. The A2AR plays a predominant role in the somnogenic effects of PGD [2]. By use of gene-manipulated mice, the arousal effect of caffeine was shown to be dependent on the A2AR. On the other hand, inhibition of wake-promoting neurons via the A1R also mediates the sleep-inducing effects of adenosine, whereas activation of A1R in the lateral preoptic area induces wakefulness, suggesting that A1R regulates the sleep-wake cycle in a site-dependent manner [48, 49]. Because these changes appear to be more pronounced in the basal forebrain (BF) than in other cerebral regions, local release of adenosine in BF was proposed to provide a signal for the homeostatic regulation of non-REM sleep [50].

Caffeine is a component of tea, coffee and cola drinks, and caffeine is the most commonly ingested methylxanthines. Moreover, caffeine, as well as related methylxanthines such as theophylline and aminophylline, is widely used as medications to treat asthma and apnea in the newborn. Caffeine is also present in many over-the-counter medications, such as in headache preparations in association with aspirin and in appetite suppressants [51].

About action mechanisms in the central nervous system there are at least three hypothesis: intracellular mobilization of calcium, inhibition of phosphodiesterases, and antagonism at the level of adenosine receptors [51].

Caffeine is the most frequently used central nervous system (CNS) stimulant in the world [52]. It is a methyl xanthine that is rapidly absorbed when taken orally, with a distribution volume similar to that of total body water and a half-life of approximately 3–8 h [53]. The waking effect of caffeine is likely due to a non-selective blockade of adenosine receptors, particularly the A1 and A2A receptors [48]. Antagonism of the A1 adenosine receptors on wake active basal forebrain cholinergic neurons may prevent them from being silenced [54]. Similarly blockade of the adenosine A2A receptors may prevent the sleep-active neurons in the preoptic area from becoming active [55]. The effects of caffeine on sleep architecture have been shown in normal volunteers [48, 56] and insomniac patients [57], caffeine is capable of antagonizing the cognitive impairment produced by prolonged sleep deprivation [58]. In rats, we determined that a reduction in sensitivity or number of adenosine receptors might contribute to the decline in sleep drive with aging [55, 59].

CAFFEINE INTAKE COULD HAVE A NEUROPROTECTIVE EFFECT IN PD

In the “Honolulu Heart Program”, the main finding was that caffeine intake has an inverse association with PD, even after they correct the early study by tobacco smoking [60].
The finding was consistent whether coffee intake was determined by 24-hour recall or by food frequency questionnaire.

The pharmacological effects of caffeine could also modulate neurotransmitters and receptors systems of brainstem nuclei or striatum. Caffeine is a known central nervous system stimulant thought to act through adenosine receptor antagonism. Adenosine receptor agonists produce decreased locomotor activity in rodents, possibly through inhibition of dopamine neurotransmission [61].

Adenosine receptors modulate dopaminergic function by regulating dopamine release in presynaptic neurons and intracellular signaling in postsynaptic striatal neurons. To investigate how adenosine imposes on the action of dopamine in feeding and locomotion, genetically altered dopamine-deficient mice were treated with adenosine receptor antagonists. Acute administration of the nonselective adenosine receptor antagonist, caffeine (5–25 mg/kg i.p.), reversed the hypophagia of mutant mice and induced hyperactivity in both control and mutant animals. However, caffeine treatment elicited much less hyperactivity in dopamine-deficient mice than did L-3,4-dihydroxyphenylalanine (L-dopa) administration, which partially restores dopamine content [62].

Caffeine and tobacco had been postulated with some neuroprotective effects in PD. Inverse associations of smoking and caffeine were corroborated using families with PD, thus emphasizing smoking and caffeine as important covariates to consider in genetic studies of PD. The inverse association of smoking with PD was corroborated in twins and siblings. Meta-analysis suggests that the inverse association of PD with coffee drinking may be slightly weaker than the association with smoking [63]. To explore the possibility that caffeine helps prevent the dopaminergic deficits characteristic of PD, there was an investigation of the effects of caffeine and the adenosine receptor subtypes through which it may act in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin model of PD.

Caffeine, at doses comparable to those of typical human exposure, attenuated MPTP-induced loss of striatal dopamine and dopamine transporter binding sites. These data establish a potential neural basis for the inverse association of caffeine with the development of PD, and they enhance the potential of A2A antagonists as a novel treatment for this neurodegenerative disease [64]. The present data reveal a novel protective effect of caffeine on the pathophysiological responses of dopaminergic nigro striatal neurons in a mouse model of PD. Caffeine dose dependently attenuated the MPTP-induced depletion of functional and anatomical markers of the NS neurons targeted in PD. The neuroprotective actions of this nonspecific adenosine receptor antagonist were mimicked by multiple A2A-specific antagonists but not by an A1-specific antagonist. MPTP toxicity was also blunted in mice lacking the A2AR, confirming the role of this receptor in facilitating MPTP toxicity and supporting its contribution to the neuroprotective effect of caffeine [64].

Associations between PD and environmental measures (history, status, dosage, duration, and intensity) of smoking, coffee, caffeine, no steroidal anti-inflammatory drugs, and no steroidal anti-inflammatory drugs, were examined using generalized estimating equations with an independent correlation matrix while controlling for age and sex [65].

Individuals with PD were significantly less likely to report ever smoking. Additional measures of smoking revealed significant inverse associations with PD and trends in odds ratios. Increasing intensity of coffee drinking was inversely associated with PD. Increasing dosage and intensity of total caffeine drinking were also inversely associated, with high dosage presenting a significant inverse association for PD. There were no significant associations between non-steroidal anti-inflammatory drugs and PD [65].

**HOW CAN BE PD PREDICTED USING SLEEP DISORDERS AS AN INFORMATION SOURCES**

Neuroprotection can be defined as the consequence of any intervention that produces enduring benefits by favorably influencing underlying etiology or pathogenesis and thereby forestalling onset of illness or clinical decline [14]. Neuroprotection can be defined as the capacity of any intervention to normalize the function of injured (but not dead) neurons [14]. This implies that neurons may be dysfunctional but not irreversibly damaged and therefore capable of being restored to normal functioning. Both concepts can be included under the umbrella of ‘‘disease modification’’, which can be seen as the clinical face of Neuroprotection and/or Neurorescue.

Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers.

However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only some limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac scintillography, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening [66].

**IS CAFFEINE HYPERSENSITIVITY AND SLEEP PROBLEMS SOME KIND OF MARKER OF PD?**

Caffeine produces dose-dependent symptoms, and intoxication may develop with overconsumption [67-69]. Patients with caffeine intoxication have some clinical manifestation as nausea and emesis, which can be difficult to control. Additionally, less severe characteristic symptoms of high consumption of caffeine originate from the stimulatory and psychoactive properties of the drug. Patients may complain of agitation, nervousness, headache, tremor, and sleep disturbances [70, 71]. More life-threatening manifestations that require additional testing and treatment include tachy-dysrhythmias and electrolyte disturbances, including hypokalemia, hypomagnesaemia, and hypophosphatemia. Hyperglycemia, metabolic acidosis with increased serum lactate, and seizures
may also occur. Three mechanisms of action support caffeine action in the CNS: Intracellular mobilization of calcium, inhibition of phosphodiesterases, and antagonism at the level of adenosine receptors [57].

Anxiety disorder patients, specifically those with panic attacks are more prone to develop intolerance to caffeine. The following study compared patients with Panic Disorders (Panic D), Major Depression (MD) and MD with Panic D (MPD). The dose of 480-mg of oral caffeine challenge test was performed with a control group. The result indicates that those subjects who have anxiety problems are more likely to panic in response to the caffeine challenge test [72].

Some people that are sensitive to the anxiogenic effects of caffeine could be because some polymorphisms in the genes that encodes receptors where this drug acts. Thus, functional polymorphisms in genes relating to the central actions of caffeine may be related to anxiogenic responses.

That has been explored before [73]. In such studies it was observed an association between self-reported anxiety after caffeine and a single-nucleotide polymorphism (SNP) in the gene encoding the adenosine A2A receptor (ADORA2A).

**ADENOSINE AND DOPAMINE RECEPTORS**

The relationship between adenosine and dopamine receptors could be summarized as follows: antagonizing the actions of adenosine by caffeine indirectly potentiates dopaminergic signaling. Indeed, dopaminergic manipulations affect the behavioral properties of caffeine. Adenosine

\[ \text{A}_1 \text{ and A}_2 \text{A receptors form functional heteromeric complexes with dopamine D}_1 \text{ and D}_2 \text{ receptors [74] and there is evidence that these receptors interact at multiple levels to control cell function. First, the receptors physically interact and binding of adenosine to A}_2 \text{A reduces affinity of DRD}_2 \text{ for dopamine [75, 76]. Second, there is reciprocal antagonism at the second messenger level reducing G-protein coupling and signaling. Activation of the A}_2 \text{A receptor stimulates adenylyl cyclase activity whereas activation of DRD}_2 \text{ inhibits adenylyl cyclase activity. Thus activation of A}_2 \text{A uncouples DRD}_2 \text{ from its G protein and reduces DRD}_2 \text{ signaling. Conversely, activation of DRD}_2 \text{ counteracts signaling via A}_2 \text{A [77].} \]

The motor stimulant effects of caffeine are reduced in DRD2 knockout mice [64]. The anxiogenic induction of caffeine in healthy male and female individuals were studied. Subject who consumed less than 300 mg caffeine per week, ingested capsules containing 0, 50, 150, and 450 mg caffeine under double-blind conditions in four separate experimental sessions. Subjective anxiety was measured before and at repeated times after capsules were consumed. At the 150 mg dose of caffeine, it was found a significant association between caffeine-induced anxiety (Visual Analog Scales, VAS) and ADORA2Ars5751876 (1976C/T), rs2298383 (intron 1a) and rs4822492 (30-flank), and DRD2 rs1110976 (intron 6). Caffeine-induced anxiety (VAS) was also associated with two-loci interactions of selected ADORA2A and DRD2 polymorphisms. The lowest dose of caffeine did not increase ratings of anxiety while the highest dose increased anxiety in the majority of subjects. These findings provide support for an association between an ADORA2A polymorphism and self-reported anxiety after a moderate dose of caffeine. It is likely that other ADORA2A and DRD2 polymorphisms also contribute to responses to caffeine [78].

In support of the previous findings, there are some evidences from studies with old rats. There are significant decrements in sleep with age. These include fragmentation of sleep, increased wake time, decrease in the length of sleep bouts, decrease in the amplitude of the diurnal rhythm of sleep, decrease in rapid eye movement sleep and a profound decrease in electroencephalogram A power (0.3–4 Hz). Old rats also have less sleep in response to 12 h of prolonged wakefulness (W). That could indicate a reduction in sleep drive as something related to the old age. The mechanism contributing to the decline in sleep with aging is not known but cannot be attributed to loss of neurons implicated in sleep since the numbers of neurons in the ventral lateral preoptic area, a region implicated in generating sleep, is similar between young (3.5 months) and old (21.5 months) rats. One possibility for the reduced sleep drive with age is that sleep–wake active neurons may be stimulated less as a result of a decline in endogenous sleep factors. Adenosine (AD), is one of such sleep factor that increases after prolonged wakefulness (W). In experiment 1, microdialysis measurements of AD in the basal forebrain at 1 h intervals reveal that old (21.5 months) rats have more extracellular levels of AD compared with young rats across the 24 h diurnal cycle. In experiment 2, old rats kept awake for 6 h (first half of lights-on period) accumulated more AD compared with young rats. If old rats have more AD then why do they sleep less? To investigate whether changes in sensitivity of the AD receptor contribute to the decline in sleep, experiments 3 and 4 determined that for the same concentration of AD or the AD receptor 1 agonist, cyclohexyladenosine, old rats have less sleep compared with young rats. It was concluded that even though old rats have more AD, a reduction in the sensitivity of the AD receptor to the ligand does not transduce the AD signal at the same strength as in young rats and may be a contributing factor to the decline in sleep drive in the elderly [54].

**CONCLUSION**

The relationship between Parkinson disease, sleep, adenosine and caffeine, has been very useful to understand basic processes of sleep physiology and motor control, as well as neurological pathology. But at the same time, they can be the tools to detect the early beginnings of neurodegenerative diseases such PD. We must develop early detection programs, with periodic evaluations of factors that may go unnoticed to the patients and their families. Sleep monitorization with home devices, coupled with home computers. That could be available for home use in patients with some sleep disorders that start after the third or fourth decade of life, together with anosmia, constipation and major depression or anxiety disorders. That would be relevant on people with disproportionate caffeine side effects manifestation.

It was confirmed that patients with PD have a low consumption of caffeine from an early age. There is now evidence, that is happens because some people may be a great sensitivity for the stimulant effects of caffeine. One goal in the future would be to explore in people in the fourth decade, the tolerance of low doses of caffeine, because they could be at some risk to develop PD. Of course that with
some other early non-motor markers as sleep disorders, anosmia, intestinal problems and psychiatric disorders. We can slow down the neurodegeneration and allow people to be less incapacitated than other patients before. That is a short step, but for sure it is worthy.

**ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD</td>
<td>Adenosine</td>
</tr>
<tr>
<td>ADA</td>
<td>Adenosine Deaminize.</td>
</tr>
<tr>
<td>ADORA2A</td>
<td>Adenosine A2A receptor.</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine Triphosphate.</td>
</tr>
<tr>
<td>CNS</td>
<td>Central Nervous System.</td>
</tr>
<tr>
<td>DA</td>
<td>Dopamine.</td>
</tr>
<tr>
<td>BF</td>
<td>Basal Forebrain.</td>
</tr>
<tr>
<td>DBS</td>
<td>Deep Brain Stimulation.</td>
</tr>
<tr>
<td>GABA</td>
<td>Gama-amino-butyric acid.</td>
</tr>
<tr>
<td>Hert</td>
<td>Hypocretin.</td>
</tr>
<tr>
<td>MCH</td>
<td>Melanin concentrating hormone.</td>
</tr>
<tr>
<td>MD</td>
<td>Major Depression.</td>
</tr>
<tr>
<td>MDP</td>
<td>MD with PD.</td>
</tr>
<tr>
<td>MnPO</td>
<td>Medial Preoptic Area</td>
</tr>
<tr>
<td>MPTP</td>
<td>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.</td>
</tr>
<tr>
<td>OKT</td>
<td>Ortho-Kung T cells. Those cells that recognized by monoclonal antibodies to T-lymphocyte antigens.</td>
</tr>
<tr>
<td>Panic D</td>
<td>Panic Disorders.</td>
</tr>
<tr>
<td>PD</td>
<td>Parkinson Disease.</td>
</tr>
<tr>
<td>PG</td>
<td>Prostaglandins.</td>
</tr>
<tr>
<td>POAH</td>
<td>Preoptic Anterior Hypothalamus.</td>
</tr>
<tr>
<td>RBD</td>
<td>REM Sleep Behavior Disorder.</td>
</tr>
<tr>
<td>REM</td>
<td>Rapid Eye Movement.</td>
</tr>
<tr>
<td>SN</td>
<td>Substantia Nigra.</td>
</tr>
<tr>
<td>SNpc</td>
<td>Substantia Nigra pars compacta</td>
</tr>
<tr>
<td>SNP</td>
<td>Single-nucleotide polymorphism.</td>
</tr>
<tr>
<td>VAS</td>
<td>Visual Analog Scales</td>
</tr>
<tr>
<td>VLPO</td>
<td>Ventral Lateral Pre Optic</td>
</tr>
</tbody>
</table>

**CONFLICT OF INTEREST**

The authors confirm that this article content has no conflicts of interest.

**ACKNOWLEDGEMENTS**

No financial contribution has support this work, other than my University (National Autonomous University of Mexico).

**REFERENCES**


